Hematology-Oncology

G3BP2-Mediated Venetoclax Resistance via ELF1-Driven MCL1 Transcription in Acute Myeloid Leukemia: Mechanisms and Therapeutic Implications

By MedXY 07/24/2026

This review synthesizes evidence on the role of RNA-binding protein G3BP2 in conferring venetoclax resistance in AML through stabilizing ELF1 mRNA and upregulating MCL1 transcription, highlighting novel therapeutic avenues combining G3BP2 inhibition with venetoclax.

Hematology-Oncology news

Measurable Residual Disease as a Prognostic Biomarker in Frontline Azacitidine and Venetoclax-Treated AML: Insights from the French VENAURA Registry

By MedXY 07/20/2026

In AML patients receiving frontline azacitidine and venetoclax, achieving measurable residual disease negativity strongly predicts longer survival and lower relapse rates, overriding baseline risk factors, as shown in the French VENAURA registry.

Hematology-Oncology news

Blinatumomab Consolidation in High-Risk Ph-Negative B-Cell Acute Lymphoblastic Leukemia: Insights from the GRAALL-2014/B-QUEST Study

By MedXY 07/20/2026

The GRAALL-2014/B-QUEST study demonstrates that integrating blinatumomab into consolidation and maintenance therapy significantly improves outcomes for adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Hematology-Oncology news Oncology

EIF4A3-Driven Nonsense-Mediated Decay: A Novel Regulatory Axis Modulating AML1-ETO9a Dosage and Clinical Outcomes in t(8;21) Acute Myeloid Leukemia

By MedXY 07/17/2026

This review highlights how EIF4A3-dependent nonsense-mediated mRNA decay selectively regulates the oncogenic AML1-ETO9a isoform in t(8;21) AML, influencing leukemic cell proliferation, chemosensitivity, and patient survival through an isoform-specific dosage checkpoint.

Hematology-Oncology news

Unraveling MDM4 Haploinsufficiency: A Novel TP53-Dependent Mechanism Driving Bone Marrow Failure Syndromes

By MedXY 07/17/2026

MDM4 haploinsufficiency activates p53, causing diverse bone marrow failure phenotypes and hypocellular MDS, highlighting the pivotal MDM4-p53 axis in hematopoietic regulation and potential targets for intervention.

Hematology-Oncology news Oncology

Navigating Dual Resistance in Extranodal NK/T-Cell Lymphoma: Challenges and Emerging Insights

By MedXY 07/15/2026

Dual resistance to asparaginase and PD-1 inhibitors in extranodal NK/T-cell lymphoma leads to poor prognosis; chidamide-containing regimens show promising survival benefits in this difficult-to-treat population.

Cardiology Hematology-Oncology news

Molecular Mutations and Cardiovascular Risks Shape Prognosis in Triple-Negative Essential Thrombocythemia

By MedXY 07/15/2026

This study reveals that specific gene mutations and cardiovascular risk factors significantly influence prognosis and thrombotic risk in triple-negative essential thrombocythemia, highlighting the importance of molecular profiling for personalized treatment.

Hematology-Oncology news

Noncanonical FLT3-ITD Signaling Drives Immune Evasion via PKCι-STAT1–Mediated CD8+ T-Cell Exhaustion in Acute Myeloid Leukemia

By MedXY 07/15/2026

FLT3-ITD mutations in AML promote immune evasion through a novel PKCι–STAT1 signaling axis that induces CD276-mediated CD8+ T-cell exhaustion, offering a promising target for combined FLT3 and CD276-directed therapies.

Hematology-Oncology news

Early Software-Assisted Evaluation Enhances Prediction of Survival in Newly Diagnosed Chronic Graft-versus-Host Disease Patients

By MedXY 07/13/2026

Software-assisted response evaluation at six months reliably predicts survival outcomes in chronic graft-versus-host disease, offering a promising tool to guide treatment decisions and improve patient prognosis.

$Pavurutamab, a BCMA-Targeting Bispecific T-Cell Engager: Promising Phase 1/1b Results in Triple-Class Relapsed/Refractory Multiple Myeloma$

Hematology-Oncology news Oncology

Pavurutamab, a BCMA-Targeting Bispecific T-Cell Engager: Promising Phase 1/1b Results in Triple-Class Relapsed/Refractory Multiple Myeloma

By MedXY 07/13/2026

Pavurutamab demonstrates manageable safety and encouraging efficacy in heavily pretreated relapsed/refractory multiple myeloma, showing an overall response rate of 46.5% and median progression-free survival of 16.8 months at the recommended dose.

Hematology-Oncology news

Fludarabine with Treosulfan vs. Total Body Irradiation as Conditioning in ALL Transplantation: A Comparative Retrospective Analysis

By MedXY 07/12/2026

This retrospective matched-pair study compares fludarabine combined with treosulfan or total body irradiation as conditioning regimens before allogeneic stem cell transplantation in adult acute lymphoblastic leukemia, finding no significant differences in key transplant outcomes.

Hematology-Oncology news

Unraveling Genetic Drivers in Triple Negative Thrombocytosis: Implications of MPL and SH2B3/LNK Mutations

By MedXY 07/12/2026

Comprehensive genetic screening of triple negative thrombocytosis reveals germline MPL compound mutations and truncating SH2B3/LNK alterations, offering new insights into diagnosis and personalized management.

AI Hematology-Oncology news

MAIPI: A Novel AI-Powered Prognostic Index for Mantle Cell Lymphoma Using Routine Histology

By MedXY 07/12/2026

The MAIPI deep learning model offers a novel, accurate prognosis tool for mantle cell lymphoma, using standard H&E stained biopsy images, bypassing need for molecular tests or expert pathology, and enhancing risk stratification for individualized therapy.

Hematology-Oncology news Pathology & Lab Medicine

Decoding PIEZO1 Variants: Precision Insights into Hereditary Red Blood Cell and Iron Disorders

By MedXY 07/12/2026

This study refines the classification of PIEZO1 variants using integrative genomic and phenotypic data, enhancing diagnosis and personalized management of hereditary red blood cell and iron disorders like dehydrated hereditary stomatocytosis.

Hematology-Oncology news Ophthalmology

Synergistic Impact of Clonal Hematopoiesis and Genetic Predisposition on Age-Related Macular Degeneration Risk: Insights from a Large UK Biobank Cohort

By MedXY 07/11/2026

This cohort study reveals that clonal hematopoiesis of indeterminate potential (CHIP) independently increases age-related macular degeneration (AMD) risk, with amplified effects when combined with high genetic susceptibility, especially in older adults.

Hematology-Oncology news

CHIME: A Novel HLA Eplet Model Predicting Non-Relapse Mortality in Haploidentical Hematopoietic Cell Transplantation

By MedXY 07/09/2026

This study introduces CHIME, a novel HLA eplet mismatch model, revealing its association with non-relapse mortality and severe aGvHD in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide, improving outcome prediction over traditional allele mismatch methods.

Clinical Updates Hematology-Oncology news

Long-term Outcomes of Oral Decitabine/Cedazuridine Plus Venetoclax in Older or Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia

By MedXY 07/09/2026

Oral decitabine/cedazuridine plus venetoclax provides an effective, fully oral frontline therapy for older or unfit patients with AML, showing encouraging response rates and manageable safety with long-term follow-up, highlighting particular challenges in secondary AML.

Hematology-Oncology news Oncology

Decoding Resistance to Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm: The Role of TXNRD1 and TET2 Mutations

By MedXY 07/09/2026

This article explores how decreased TXNRD1 expression and specific TET2 mutations are linked to tagraxofusp resistance in BPDCN patients, highlighting biomarkers that could guide future therapeutic strategies.

Hematology-Oncology news

Unveiling Non-PF4/Heparin-Binding, Platelet-Activating Antibodies in Heparin-Induced Thrombocytopenia: Implications for Diagnosis and Pathogenesis

By MedXY 07/09/2026

Recent findings identify a prevalent subset of platelet-activating antibodies in HIT that evade traditional PF4/heparin ELISA detection, highlighting new diagnostic and pathogenic insights.

Hematology-Oncology news Ophthalmology

Evaluating the ISOLD Score for Accurate Diagnosis of Vitreoretinal Lymphoma in Clinical Practice

By MedXY 07/09/2026

This study validates the ISOLD score, a cytokine-based probabilistic tool, demonstrating high sensitivity and specificity for diagnosing vitreoretinal lymphoma from aqueous humor samples, outperforming standard IL-10/IL-6 ratios, with implications for improved clinical decision-making.